EP1306434B1 - Gene welche für proteine, die befähigt sind luziferin zu regenerieren, kodieren, rekombinante dna und verfahren zur herstellung von proteinen, die befähigt sind luziferin zu regenerieren - Google Patents

Gene welche für proteine, die befähigt sind luziferin zu regenerieren, kodieren, rekombinante dna und verfahren zur herstellung von proteinen, die befähigt sind luziferin zu regenerieren Download PDF

Info

Publication number
EP1306434B1
EP1306434B1 EP01954352A EP01954352A EP1306434B1 EP 1306434 B1 EP1306434 B1 EP 1306434B1 EP 01954352 A EP01954352 A EP 01954352A EP 01954352 A EP01954352 A EP 01954352A EP 1306434 B1 EP1306434 B1 EP 1306434B1
Authority
EP
European Patent Office
Prior art keywords
dna
luciferin
regenerating
seq
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP01954352A
Other languages
English (en)
French (fr)
Other versions
EP1306434A4 (de
EP1306434A1 (de
Inventor
Kozo Hirokawa
Keiko Kurosawa
Naoki Kajiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kikkoman Corp
Original Assignee
Kikkoman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kikkoman Corp filed Critical Kikkoman Corp
Publication of EP1306434A1 publication Critical patent/EP1306434A1/de
Publication of EP1306434A4 publication Critical patent/EP1306434A4/de
Application granted granted Critical
Publication of EP1306434B1 publication Critical patent/EP1306434B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects

Definitions

  • the present invention relates to a gene encoding a protein that is capable of regenerating luciferin, a recombinant DNA, and a process for producing a protein capable of regenerating luciferin.
  • Luciferin is a substrate of luciferase, a bioluminescence enzyme. After emitting light as a result of luciferase reaction, luciferin is converted into oxyluciferin.
  • ATP measurement methods using luciferase are widely used in the fields of medicine and food hygiene.
  • luciferin used as a substrate is expensive and the luciferase reaction is inhibited by oxyluciferin produced after the reaction.
  • removal of oxyluciferin or regeneration to luciferin is considered to enable further development of the ATP measurement methods using luciferase.
  • a protein which is derived from a firefly and capable of regenerating luciferin from oxyluciferin has been found (U.S. Pat. No. 5814504). However, only a small quantity of the protein can be extracted from a firefly body so that industrial application of this protein has been difficult.
  • the object of the present invention is to provide a process for producing a protein capable of regenerating luciferin, using a recombinant DNA producing the protein capable of regenerating luciferin.
  • the present inventors have succeeded in isolating a gene which is derived from Coleoptera and which encodes a protein capable of regenerating luciferin, determining the gene structure of the same, and obtaining a recombinant DNA by inserting a gene encoding a protein capable of regenerating luciferin into a vector DNA. Then, the present inventors have completed the present invention by finding that a protein capable of regenerating luciferin can efficiently be produced by culturing a transformant or a transductant wherein the recombinant DNA is contained in a host cell.
  • a first invention of the present application is an isolated or synthesized gene which encodes a protein comprising the amino acid sequence represented by SEQ ID NO: 2.
  • a second invention of the present application is an isolated or synthesized gene which hybridizes with the complementary strand sequence of a DNA comprising the nucleotide sequence represented by SEQ ID NO: 1 under stringent conditions and encodes a protein capable of regenerating luciferin.
  • a third invention of the present application is a recombinant DNA, which is characterized in that the above-described isolated or synthesized gene is inserted into a vector DNA.
  • a fourth invention of the present application is a transformant or transductant comprising the above-described recombinant DNA.
  • a fifth invention of the present application is a process for producing a protein capable of regenerating luciferin, which is characterized in that the process comprises culturing the above-described transformant or transductant in a medium, and collecting therefrom the protein capable of regenerating luciferin.
  • luciferin-regenerating enzyme capable of regenerating luciferin may at times simply be abbreviated as a "luciferin-regenerating enzyme”.
  • a DNA encoding the protein capable of regenerating luciferin or a DNA encoding the protein capable of regenerating luciferin and further comprising a non-translation region may at times be abbreviated as a "luciferin-regenerating enzyme gene”.
  • the gene of the present invention encoding a protein capable of regenerating luciferin is obtained from Coleoptera having a luciferin-luciferase reaction.
  • the gene encoding a protein capable of regenerating luciferin of the present invention as defined in the claims includes a gene encoding the amino acid sequence represented by SEQ ID NO: 2 of the sequence listing, and a gene comprising the nucleotide sequence represented by SEQ ID NO: 1 of the sequence listing. Taking codon degeneracy into consideration, the gene encoding the amino acid sequence represented by SEQ ID NO: 2 of the sequence listing includes various nucleotide sequences.
  • the gene encoding the amino acid sequence represented by SEQ ID NO: 2 may be selected from among such various nucleotide sequences, considering various elements of a gene expression system such as a preferred codon based on the type of a host cell and prevention of a higher order structure formed by a transcribed RNA.
  • the selected nucleotide sequence may be either a DNA cloned from the nature or an artificial chemically synthesized DNA.
  • a poly(A) + RNA is first prepared from a Genji firefly by the following method.
  • a method of extracting the total RNA from Coleoptera tissues is not limited as long as the method can efficiently obtain RNA with minimal damage.
  • known methods such as the phenol/SDS method and the guanidine isothiocyanate/cesium chloride method can be applied.
  • Poly(A) + RNA can be separated from the thus obtained total RNA using an oligo(dT) carrier. Otherwise, a kit which obtains poly(A) + RNA without extracting the total RNA may also be used (MPG Direct mRNA Purification Kit, CPG, INC. etc.)
  • a single stranded cDNA is synthesized with reverse transcriptase, using the poly(A) + RNA as a template and also using oligo(dT) primers, random primers or the like. Thereafter, a double stranded cDNA is synthesized by the Gubler and Hoffman method, the Okayama-Berg method (Molecular Cloning, 2 nd edition, Cold Spring Harbor Press, 1989) or others.
  • the cDNA may be amplified by PCR, using a cDNA library preparation kit [Capfinder PCR cDNA Library Construction Kit (CLONTECH) etc.]
  • the thus synthesized cDNA can be cloned into a cloning vector such as a phage vector or plasmid by blunt-ending, adding a linker, adding restriction sites by PCR and others.
  • the partial sequence of the gene of interest can be obtained by performing PCR (polymerase chain reaction), using the thus obtained cDNA or cDNA library as a template.
  • the sequence used as a primer herein may be based on any part of the amino acid sequence of the luciferin-regenerating enzyme, but it is desired to select a sequence which has fewer codon degeneracy and does not form a complicated higher order structure. Where there is codon degeneracy, mixed primers or primers containing inosine can be used. Whether the amplified product obtained by PCR is a part of a luciferin-regenerating enzyme gene is easily confirmed by analysis of the nucleotide sequence using a 370A DNA sequence system (PerkinElmer).
  • primers are prepared from the sequence, and 5'RACE and 3'RACE (Rapid Amplification of cDNA End: PCR PROTOCOLS A Guide to Methods and Applications, ACADEMIC press INC. p.28-38) are carried out to determine unknown 5'- and 3'-terminal regions. According to the above operations, a full-length luciferin-regenerating enzyme gene is easily sequenced.
  • 5'RACE and 3'RACE for example, 5'-Full RACE Core Set (TaKaRa) and 3'-Full RACE Core Set (TaKaRa) can be used.
  • a DNA fragment used as a probe can be obtained by PCR, using, as primers, oligonucleotides synthesized on the basis of the amino acid sequence of a luciferin-regenerating enzyme.
  • the obtained DNA fragment can be converted into a probe by labeling.
  • labeling various substances such as radioisotope or biotin can be applied, but labeling by the random priming method is desirable.
  • the preparation of a cDNA library can be carried out, for example, using a ZAP Express Vector Kit of STRATAGENE.
  • the labeling of a DNA fragment and the detection of hybridization can be carried out, for example, using a DIG DNA labeling/detection system (Boehringer Mannheim) or the like.
  • stringent conditions means conditions where only a specific hybrid is selectively formed and a signal is detected, while a non-specific hybrid is not formed. Although these conditions are different depending on each species of organism, the conditions can easily be determined by analyzing certain properties such as salt concentration or temperature for hybridization and washing process according to standard techniques. As such conditions, hybridization is carried out overnight (approximately 8 to 16 hours) using 5 x SSC, a 1.0% (W/V) nucleic acid blocking reagent for hybridization (Boehringer Mannheim), 0.1% (W/V) N-lauroyl sarcosine and 0.02% (W/V) SDS.
  • 0.1 x SSC and 0.1% (W/V) SDS are used, the concentration of SSC is set within the range of 0.1 fold, and the washing is started at a temperature of 37°C and then increased to 65°C. Under such conditions, a membrane is washed so that a fixed DNA-derived signal can be differentiated from the background, and thereafter the detection of a probe is carried out.
  • a DNA hybridized under these conditions has a high probability of encoding a polypeptide having a luciferin-regenerating enzyme activity, but it also includes a mutant DNA which might cause the luciferin-regenerating enzyme activity to be lost.
  • a mutant DNA can easily be eliminated by determining, after performing transformation, the ability of the transformant to generate a luciferin-regenerating enzyme activity.
  • a luciferin-regenerating enzyme gene is obtained by the above-described method, the gene is incorporated into a vector DNA by standard techniques.
  • a vector DNA used herein include a plasmid DNA such as pUC19(Takara Shuzo), pBR322 (Takara Shuzo), pT7Blue (Novagen), pBluescript SK+ (Stratagene) and pMAL-C2 (NEW England Labs), a bacteriophage DNA such as ⁇ ENBL3 (Stratagene) and ⁇ DASH II (Funakoshi), and others.
  • the obtained recombinant DNA is transformed or transduced into, for example, Escherichia coli K-12, preferably Escherichia coli JM109 (Toyobo), DH5 ⁇ (Toyobo) or XL1-Blue (Funakoshi), thereby obtaining a transformant or transductant, respectively.
  • Escherichia coli K-12 preferably Escherichia coli JM109 (Toyobo), DH5 ⁇ (Toyobo) or XL1-Blue (Funakoshi)
  • examples of a host cell used herein include bacteria such as Escherichia coli other than E. coli K-12, yeast, mold, Actinomycetes, silk worms, animal cells and others.
  • Transformation can be carried out by, for example, D. M. Morrison's method (Method in Enzymology, 68, 326-331, 1979). Transduction can be carried out by, for example, B. Hohn's method (Method in Enzymology, 68, 299-309, 1979).
  • a purified recombinant DNA can be obtained from the above transformant or transductant by, for example, P. Guerry et al.'s method [J. Bacteriology, vol. 116, 1064-1066 (1973)] and D. B. Clewell's method [J. Bacteriology, vol. 110, 667-676 (1972)].
  • nucleotide sequence of the gene encoding a protein capable of regenerating luciferin is analyzed (see SEQ ID NO: 1) using a DNA comprising the above luciferin-regenerating enzyme gene and a 370A DNA sequence system (PerkinElmer) indicated in the later described Example 1, Item (9). Then, the primary sequence of the amino acids of a polypeptide translated by a gene comprising the above nucleotide sequence, is determined (see SEQ ID NO: 2).
  • a transformant or transductant capable of regenerating luciferin obtained as described above for example, a strain belonging to the genus Escherichia , a protein capable of regenerating luciferin can be produced as described below.
  • the above microorganism may be cultured by any normal solid culture method, but it is preferably cultured by a liquid culture method.
  • a medium used for culturing the above microorganism is supplemented with, for example, one or more types of nitrogen source such as yeast extract, Peptone, meat extract, corn steep liquor, or exudates of soybean or wheat koji, and one or more types of inorganic salt such as potassium dihydrogenphosphate, dipotassium hydrogenphosphate, magnesium sulfate, ferric chloride, ferric sulfate or manganese sulfate, and if necessary, this medium is appropriately supplemented with carbohydrate material, vitamin and the like.
  • nitrogen source such as yeast extract, Peptone, meat extract, corn steep liquor, or exudates of soybean or wheat koji
  • inorganic salt such as potassium dihydrogenphosphate, dipotassium hydrogenphosphate, magnesium sulfate, ferric chloride, ferric sulfate or manganese sulfate, and if necessary, this medium is appropriately supplemented with carbohydrate material, vitamin and the like.
  • the initial pH of a medium is appropriately adjusted to 7 to 9.
  • culture is performed at 30°C to 42°C, preferably at around 37°C for 6 to 24 hours by aeration agitation-submerged culture, shaking culture, stationary culture or the like.
  • the protein capable of regenerating luciferin can be collected from the culture product by normal techniques for collecting enzymes.
  • Cells are isolated from the culture product by an operation such as filtration or centrifugation and are then washed.
  • a luciferin-regenerating enzyme is preferably collected from these cells.
  • intact cells can directly be used, but preferably, the luciferin-regenerating enzyme is collected from the cells by, for example, a method which disrupts cells using various disruptive means such as an ultrasonicator, French press or Dynamill, a method which digests cell walls using a cell wall digesting enzyme such as lysozyme, and a method which extracts the enzyme from the cells using a surfactant such as Triton X-100.
  • the luciferin-regenerating enzyme can be isolated from the thus obtained crude cell homogenization solution containing the enzyme by any standard enzyme purification technique. Preferably performed is an appropriate combination of such techniques including ammonium sulfate salting out technique, precipitation technique using organic solvents, ion exchange chromatography, gel filtration chromatography, adsorption chromatography and electrophoresis.
  • the ability of the enzyme to regenerate luciferin can be measured by the following method.
  • RNA fraction 0.5 mg was obtained according to the method described in Current Protocols in Molecular Biology (WILEY Interscience, 1989).
  • Primers were prepared on the basis of a Genji firefly-derived luciferin-regenerating enzyme (U.S. Pat. No. 5814504, Example 2) which was separately obtained by the present inventors. Initially, a Genji firefly-derived luciferin-regenerating enzyme was fragmentized with peptidase and the obtained product was subjected to reversed-phase partition chromatography to obtain a peak. Using an ABI470A protein sequencer (PerkinElmer), the amino acid sequences of the obtained several types of peptides were determined. Based on the thus determined amino acid sequences, primers of KN14 (SEQ ID NO: 3) and GC3 (SEQ ID NO: 4) were designed, and synthesis was carried out by the custom DNA synthesis service of Amersham Pharmacia Biotech.
  • KN14 SEQ ID NO: 3
  • GC3 SEQ ID NO: 4
  • a reaction solution was prepared to have the following composition, and a reverse transcription reaction was allowed to proceed at 42°C for 30 minutes. Thereafter, denaturation was performed at 99°C for 5 minutes, and the obtained reaction product was then stored at 5°C.
  • Composition of reaction solution Amount used 25 mM MgCl 2 4 ⁇ l *10xRNA PCR buffer 2 ⁇ l 10 mM dNTP Mixture 2 ⁇ l 40 U/ ⁇ l RNase Inhibitor 0.5 ⁇ l 5 U/ ⁇ l *AMV reverse transcriptase XL 1 ⁇ l 2.5 pmol/ ⁇ l *oligo dT-Adaptor primer 1 ⁇ l mRNA 1 ⁇ g Sterile distilled water add water to a final volume of 20 ⁇ l *manufactured by Takara Shuzo
  • reaction solution prepared to have the following composition was added to a tube in which reverse transcription had been performed. Then, PCR was performed for 30 cycles under the following reaction conditions: denaturation at 94°C for 30 seconds, annealing at 62°C for 30 seconds, and elongation reaction at 72°C for 1.5 minutes.
  • composition of reaction solution Amount used 20 pmol/ ⁇ l primer KN14 (SEQ ID NO: 3) 1 ⁇ l 20 pmol/ ⁇ l primer GC3 (SEQ ID NO: 4) 1 ⁇ l *10xRNA PCR buffer 8 ⁇ l 25 mM MgCl 2 6 ⁇ l 5 U/ ⁇ l *Taq polymerase 0.5 ⁇ l Sterile distilled water 63.5 ⁇ l *manufactured by Takara Shuzo
  • the reaction solution was subjected to agarose gel electrophoresis, so that a band in a position of approximately 900 bp regarded as a target amplified fragment was confirmed.
  • the band was cut out and purified with GENECLEAN II (BIO 101).
  • the nucleotide sequence of the purified DNA fragment was determined and analyzed using a 370A DNA sequence system (PerkinElmer). Thus, an amino acid sequence which had been deduced from the determined nucleotide sequence was confirmed to comprise the peptide fragment obtained in (2).
  • a primer was designed according to the above analysis for DNA sequence, and then synthesized by the synthesis service of Amersham Pharmacia Biotech (GNI-2, SEQ ID NO: 5).
  • 3' RACE was performed using the primer, the above mRNA and a 3'-Full RACE CoreSet (Takara Shuzo), thereby amplifying unknown 3' regions.
  • the reaction solution was subjected to agarose electrophoresis, from which a DNA fragment of approximately 200 bp was purified and extracted with RecoChip (Takara Shuzo), and the nucleotide sequence was determined and analyzed using a DNA sequencer.
  • the 5' region of the determined nucleotide sequence was confirmed to contain a sequence being the same as that of the above gene encoding a protein capable of regenerating luciferin.
  • primers were designed according to the above analysis for DNA sequence, and then synthesized by the synthesis service of Amersham Pharmacia Biotech [GC11 (SEQ ID NO: 6), GN11 (SEQ ID NO: 7), KN11-2 (SEQ ID NO: 8), GC13 (SEQ ID NO: 9) and GC14 (SEQ ID NO: 10)].
  • RT-PCR was performed using the primers, the above Genji firefly mRNA and a 5'-Full RACE CoreSet (Takara Shuzo), thereby amplifying unknown 5' regions.
  • the reaction solution was subjected to agarose electrophoresis, a DNA fragment of approximately 850 bp was purified with RecoChip (Takara Shuzo), and the nucleotide sequence was determined and analyzed using a DNA sequencer. Thus, the 3' region of the determined nucleotide sequence was confirmed to contain a sequence being the same as that of the above gene encoding a protein capable of regenerating luciferin.
  • a translation initiation codon and a termination codon were deduced from the above three nucleotide sequences, and then the primer DNAs of the nucleotide sequences corresponding to the N-terminal region and the C-terminal region were synthesized by the synthesis service of Amersham Pharmacia Biotech [porf1 (SEQ ID NO: 11), porf2 (SEQ ID NO: 12)].
  • RT-PCR was performed using these primers and the above Genji firefly mRNA, and then the reaction solution was analyzed by agarose electrophoresis. As a result, a band of approximately 900 bp was confirmed. A DNA fragment contained in the band was purified with RecoChip (Takara Shuzo).
  • the purified DNA fragment was cloned into a plasmid pT7Blue (Novagen), and Escherichia coli JM109 was then transformed with the obtained plasmid.
  • the obtained transformant strain, Escherichia coli JM 109 (pGlre) was deposited with the National Institute of Advanced Industrial Science and Technology, an Independent Administrative Institution under the Ministry of Economy, Trade and Industry, AIST Tsukuba (Central 6, Higashi 1-1-1, Tsukuba, Ibaraki, Japan) under accession No. FERM BP-7247 on July 27, 2000.
  • E. coli JM 109 (pGlre) cells were shake-cultured to 100 Kletts at 37°C in 10 ml of a TY medium (1% bacto trypton, 0.5% bactoyeast extract, 0.5% NaCl, pH 7.0) containing 75 ⁇ g/ml ampicillin. Then, IPTG was added to reach a final concentration of 1mM, followed by another 4 hours of culture. The culture solution was treated 4 times (20 seconds each) using an ultrasonicator (Ultrasonicgenerator, Nissei) while being cooled on ice. The solution was placed into an Eppendorf tube, and centrifuged at 12,000 r.p.m.
  • Ultrasonicator Ultrasonicgenerator
  • E. coli comprising vectors only had 0.95 kcount/ml
  • E. coli JM109 (pGlre) had 11.0 kcount/ml and was confirmed to be capable of regenerating luciferin.
  • the cDNA library of a Genji firefly was prepared by using a ZAP Express Vector Kit (STRATAGENE). Then, using the amplified fragment of approximately 900 bp obtained by RT-PCR in Example 1 (3) as a template and KN14 (SEQ ID NO: 3) and GC3 (SEQ ID NO: 4) as primers, a digoxigenin (DIG)-labeled DNA probe was prepared by PCR.
  • DIG digoxigenin
  • PCR program was set at (1) 95°C, 30 seconds, (2) 95°C, 30 seconds, (3) 62°C, 30 seconds, (4) 72°C, 40 seconds and (5) 72°C, 2 minutes, and a PCR reaction was carried out such that operations (2) to (4) were repeated for 45 cycles followed by (5) 72°C, 2 minutes.
  • An amplified fragment was collected from the reaction solution by ethanol precipitation, and the fragment was dissolved in 50 ⁇ l of TE buffer so as to obtain a DIG-labeled probe.
  • plaque hybridization was carried out. According to the manual attached to the kit, approximately 5 x 10 3 plaques were formed on each of five agar mediums. Thereafter, DNA was transferred from the plaques on these mediums to a HyBond-N + nylon transfer membrane (Amersham) according to the manual attached to the membrane kit. This time, to exclude non-specific signals, DNA was transferred from a single agar medium to two membranes.
  • Hybridization and detection were carried out on the above-described membranes using the prepared DIG-DNA probe and DIG system (Boehringer Mannheim) according to the descriptions on pages 37 to 40 of "User guide for performing hybridization using DIG system", Boehringer Mannheim, (1996).
  • Escherichia coli JM109 was transformed with the plasmid pGP, and a plasmid DNA was prepared from the obtained transformant and was used as a sample for analyzing the nucleotide sequence.
  • the nucleotide sequence of an inserted cDNA was analyzed by the previously known method of using a Taq DyeDeoxy Terminator Cycle Sequencing Kit (PerkinElmer). As a result, it was confirmed that the inserted cDNA had a nucleotide sequence identical to SEQ ID NO: 1 of the sequence listing and is a gene encoding a luciferin-regenerating enzyme derived from a Genji firefly.
  • the present invention is industrially very useful because the invention enables efficient production of a protein capable of regenerating luciferin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Insects & Arthropods (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (5)

  1. Isoliertes oder synthetisiertes Gen, das für ein Protein kodiert, das in der Lage ist, Luciferin zu regenerieren, worin das Gen aus der aus Folgendem bestehenden Gruppe ausgewählt ist:
    (1) einem Gen, das für ein Protein kodiert, das die durch Seq.-ID Nr. 2 dargestellte Aminosäuresequenz umfasst;
    (2) DNA, die die durch Seq.-ID Nr. 1 dargestellte Nucleotidsequenz umfasst; und
    (3) einem Gen, das mit der Sequenz des komplementären Strangs zu DNA, die die durch Seq.-ID Nr. 1 dargestellte Nucleotidsequenz umfasst, unter stringenten Bedingungen hybridisiert.
  2. Rekombinante DNA, die dadurch gekennzeichnet ist, dass ein isoliertes oder synthetisiertes Gen nach Anspruch 1 in eine Vektor-DNA insertiert ist.
  3. Transformierte Zelle, die rekombinante DNA nach Anspruch 2 umfasst.
  4. Transformierte Zelle nach Anspruch 3, die Escherichia coli ist.
  5. Verfahren zur Produktion eines Proteins, das in der Lage ist, Luciferin zu regenerieren, dadurch gekennzeichnet, dass das Verfahren das Kultivieren einer transformierten Zelle nach Anspruch 3 oder Anspruch 4 in einem Medium und das Gewinnen von Protein, das zur Regeneration von Luciferin in der Lage ist, aus der Kultur umfasst.
EP01954352A 2000-07-28 2001-07-26 Gene welche für proteine, die befähigt sind luziferin zu regenerieren, kodieren, rekombinante dna und verfahren zur herstellung von proteinen, die befähigt sind luziferin zu regenerieren Expired - Lifetime EP1306434B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000228226 2000-07-28
JP2000228226A JP3891323B2 (ja) 2000-07-28 2000-07-28 ルシフェリンを再生する能力を有するタンパク質をコードする遺伝子、組み換え体ｄｎａ及びルシフェリンを再生する能力を有するタンパク質の製造法
PCT/JP2001/006454 WO2002010383A1 (fr) 2000-07-28 2001-07-26 Genes codant des proteines capables de regenerer la luciferine, adn recombine et methode de production de proteines capables de regenerer la luciferine

Publications (3)

Publication Number Publication Date
EP1306434A1 EP1306434A1 (de) 2003-05-02
EP1306434A4 EP1306434A4 (de) 2004-06-30
EP1306434B1 true EP1306434B1 (de) 2006-09-13

Family

ID=18721557

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01954352A Expired - Lifetime EP1306434B1 (de) 2000-07-28 2001-07-26 Gene welche für proteine, die befähigt sind luziferin zu regenerieren, kodieren, rekombinante dna und verfahren zur herstellung von proteinen, die befähigt sind luziferin zu regenerieren

Country Status (6)

Country Link
US (1) US7049113B2 (de)
EP (1) EP1306434B1 (de)
JP (1) JP3891323B2 (de)
AT (1) ATE339499T1 (de)
DE (1) DE60123077T2 (de)
WO (1) WO2002010383A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178450A1 (en) * 2006-01-27 2007-08-02 Microphage (Tm) Incorporation Method and apparatus for determining level of microorganisms using bacteriophage
WO2010147066A1 (ja) * 2009-06-15 2010-12-23 オリンパスメディカルシステムズ株式会社 被検体内導入装置および生体内情報取得システム
CN101955528B (zh) * 2010-08-05 2012-07-04 许爱娥 人mchr1抗原表位区基因表达相关蛋白mchr1-c及其编码基因

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814504A (en) * 1996-08-22 1998-09-29 Kikkoman Corporation Protein involved in regenerating firefly luciferin
JP2001103972A (ja) * 1999-10-06 2001-04-17 Kikkoman Corp ルシフェリンを再生する能力を有するタンパク質をコードする遺伝子、新規な組み換え体ｄｎａ及びルシフェリンを再生する能力を有するタンパク質の製造法

Also Published As

Publication number Publication date
DE60123077T2 (de) 2007-03-29
DE60123077D1 (de) 2006-10-26
EP1306434A4 (de) 2004-06-30
US20040185441A1 (en) 2004-09-23
JP3891323B2 (ja) 2007-03-14
JP2002034573A (ja) 2002-02-05
US7049113B2 (en) 2006-05-23
WO2002010383A1 (fr) 2002-02-07
EP1306434A1 (de) 2003-05-02
ATE339499T1 (de) 2006-10-15

Similar Documents

Publication Publication Date Title
US5418155A (en) Isolated Renilla luciferase and method of use thereof
EP0575319A1 (de) Klonierung und expression der luziferase aus renilla
EP3473717A1 (de) Mutierte coleoptera luciferase, gen, rekombinanter vektor, transformant und verfahren zur herstellung von mutierter coleoptera luciferase
EP1156103B1 (de) Oplophorus Luciferase
EP1306435B1 (de) GENE, WELCHE FüR LUZIFERIN REGENERIERENDE PROTEINE KODIEREN, REKOMBINANTE DNA UND VERFAHREN ZUR HERSTELLUNG EINES LUZIFERIN REGENERIERENDEN PROTEINS
JP3048466B2 (ja) 耐熱性ホタルルシフェラーゼ、耐熱性ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ、及び耐熱性ホタルルシフェラーゼの製造法
US7871803B2 (en) Gene encoding novel luciferase
EP1306434B1 (de) Gene welche für proteine, die befähigt sind luziferin zu regenerieren, kodieren, rekombinante dna und verfahren zur herstellung von proteinen, die befähigt sind luziferin zu regenerieren
CN115074338B (zh) 突变型甲虫荧光素酶、基因、重组载体、转化体以及突变型甲虫荧光素酶的制备方法
EP0877084B1 (de) Für temperaturstabiles Diaphorase Kodierendes Gen
EP1020524B1 (de) Mutiertes bioluminiszenz-protein und verfahren für seine herstellung.
EP1229114B1 (de) Gen, welches ein protein kodiert, das luciferin regeneriert, neue rekombinante dna und verfahren zur herstellung des genannten proteins
JPH10108679A (ja) ピルベートオルトフォスフェートジキナーゼ遺伝子、組み換え体ｄｎａ及びピルベートオルトフォスフェートジキナーゼの製造法
JP3498808B2 (ja) Ｄｎａポリメラーゼ遺伝子
EP1707621B1 (de) Mutiertes Biolumineszenz-Protein und Verfahren zu dessen Herstellung
JP2002335961A (ja) 渦鞭毛藻ルシフェラーゼ及びそれをコードする遺伝子
JPH10225293A (ja) 耐熱性グルコース−６−リン酸脱水素酵素遺伝子、新規な組み換え体ｄｎａ及び耐熱性グルコース−６−リン酸脱水素酵素の製造法
JPH1189581A (ja) アルコール脱水素酵素、アルコール脱水素酵素遺伝子、新規な組み換え体ｄｎａ及びアルコール脱水素酵素の製造法
JPH09131185A (ja) 新規なｎａｄｈキナーゼ遺伝子、新規な組み換え体ｄｎａ 及びｎａｄｈキナーゼの製造法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030217

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

A4 Supplementary search report drawn up and despatched

Effective date: 20040513

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 9/02 B

Ipc: 7C 12N 15/12 A

Ipc: 7C 07K 14/435 B

17Q First examination report despatched

Effective date: 20040816

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060913

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60123077

Country of ref document: DE

Date of ref document: 20061026

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061213

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070226

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20070719

Year of fee payment: 7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070731

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061214

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20070710

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090203

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20090331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070726

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110720

Year of fee payment: 11

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120726